Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.
Nieborowska-Skorska M, et al. Among authors: skorski t.
Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.
Blood. 2017.
PMID: 29042365
Free PMC article.